A phase I study of AEG35156 given as a 2 hour intravenous infusion in combination with docetaxel in patients with solid tumours.
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2016
At a glance
- Drugs AEG 35156 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- 09 Jan 2012 Actual end date changed from (1 Mar 2009) to (1 Jan 2012) as reported by ClinicalTrials.gov.
- 16 Sep 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 16 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.